Cited by 605CAR-T cell therapy researchCancer Immunotherapy and BiomarkersOccupational and environmental lung diseases

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Open access

Adusumilli, Prasad S., Zauderer, Marjorie G., Rivière, Isabelle, Solomon, Stephen B., Rusch, Valerie W., O'Cearbhaill, Roisin E., Zhu, Amy, Cheema, Waseem, Chintala, Navin K., Halton, Elizabeth, Pineda, John, Perez-Johnston, Rocio, Tan, Kay See, Daly, Bobby, Araujo Filho, Jose A., Ngai, Daniel, McGee, Erin, Vincent, Alain, Diamonte, Claudia, Sauter, Jennifer L., Modi, Shanu, Sikder, Devanjan, Senechal, Brigitte, Wang, Xiuyan, Travis, William D., Gönen, Mithat, Rudin, Charles M., Brentjens, Renier J., Jones, David R., Sadelain, Michel·2021·Cancer Discovery

DOI 10.1158/2159-8290.cd-21-0407PMC PMC8563385

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I study of regionally delivered, autologous, mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy. Intrapleural administration of 0.3M to 60M CAR T cells/kg in 27 patients (25 with MPM) was safe and well tolerated. CAR T cells were detected in peripheral blood for >100 days in 39% of patients. Following our demonstration that PD-1 blockade enhances CAR T-cell function in mice, 18 patients with MPM also received pembrolizumab safely. Among those patients, median overall survival from CAR T-cell infusion was 23.9 months (1-year overall survival, 83%). Stable disease was sustained for ≥6 months in 8 patients; 2 exhibited complete metabolic response on PET scan. Combination immunotherapy with CAR T cells and PD-1 blockade agents should be further evaluated in patients with solid tumors. Significance: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is feasible, safe, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors. See related commentary by Aldea et al., p. 2674. This article is highlighted in the In This Issue feature, p. 2659

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0407

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Self-citation
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,098
Self-citation
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J. F., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,062
Self-citation
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial
Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Self-citation
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
Self-citation

Show all 37 references

Sorted by citations

Items 301–400 of 599

The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma
Perera, N. D., & Mansfield, A. S. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01302-3 · Cited by 9
Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma
Rondon, L., Fu, R., & Patel, M. R. (2023) · Cancers · doi:10.3390/cancers15112940 · Cited by 9
Contemporary management of mesothelioma
Neilly, M. D. J., Pearson, J., Thu, A. W., MacRae, C., & Blyth, K. G. (2024) · Breathe · doi:10.1183/20734735.0175-2023 · Cited by 8
Validation of a PD-1/CD28 chimeric switch receptor to augment CAR-T function in dogs with spontaneous B cell lymphoma
Yoshimoto, S., Kudo, A., Rotolo, A., Foos, K. M., Olenick, L. K., Takagi, S., & Mason, N. J. (2024) · iScience · doi:10.1016/j.isci.2024.110863 · Cited by 8
Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities
Reinhorn, D. J., Tak, W. S., Haanen, J. B. A. G., D’Angelo, S. P., & Fashoyin‐Aje, L. A. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473440 · Cited by 8
Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions
Althafar, Z. M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1614325 · Cited by 8
Innovative strategies for improving CAR-T cell therapy: A nanomedicine perspective
Wang, M., Yu, Z., Yuan, L., Yang, P., Jing, C., Qu, Y., Qian, Z., & Niu, T. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003706 · Cited by 8
CAR-T for Lung Cancers: Challenges and Innovations
Trudu, L., Rovesti, G., Neri, G., Pugliese, G., Silingardi, M., Brini, L., Golinelli, G., Baschieri, M. C., Lallo, E., Guaitoli, G., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108711 · Cited by 8
Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy
Sioud, M., & Casey, N. P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020909 · Cited by 9
Advances in CAR design
Heard, A. D., Chang, J., Warrington, J. M., & Singh, N. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101304 · Cited by 8
Advances in CAR T cell immunotherapy for paediatric brain tumours
Rao, P., Furst, L. M., Meyran, D., Mayoh, C., Neeson, P. J., Terry, R. L., Khuong-Quang, D.-A., Mantamadiotis, T., & Ekert, P. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.873722 · Cited by 10
The emerging role for CAR T cells in solid tumor oncology
Klobuch, S., Seijkens, T. T. P., & Haanen, J. B. A. G. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-22-125 · Cited by 8
Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy
Cedrés, S., Valdivia, A., Iranzo, P., Callejo, A., Pardo, N., Navarro, A., Martínez‐Martí, A., Assaf-Pastrana, J. D., Felip, E., & Garrido, P. (2023) · Cancers · doi:10.3390/cancers15245787 · Cited by 11
Navigating first-line therapies for extensive-stage small-cell lung cancer: a frequentist network meta-analysis and systematic review
Liu, Y., Zhu, J., Du, T., Liu, X., Xin, Y., Wang, Y., Wang, Y., Xu, J.-H., Chen, Y., Wei, H., et al. (2024) · Future Oncology · doi:10.1080/14796694.2024.2376514 · Cited by 8
Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology
Chada, N. C., & Wilson, J. T. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103179 · Cited by 8
The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence
Barzegari, A., Salemi, F., Kamyab, A., Aratikatla, A., Nejati, N., Valizade, M., Eltouny, E., & Ebrahimi, A. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100635 · Cited by 9
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
Chiec, L. S., & Bruno, D. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910861 · Cited by 8
Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors
Malhotra, J. D., Huang, A., Amini, A., & Lee, P. P. (2024) · Cancers · doi:10.3390/cancers16213603 · Cited by 8
Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis
Lai, J., Beavis, P. A., Li, J., & Darcy, P. K. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3548 · Cited by 8
Overcoming tumor antigen heterogeneity in CAR-T cell therapy for malignant mesothelioma (MM)
D’Souza, R. R., Dimou, P., Bughda, R., Hawkins, E., Leboreiro-Babe, C., & Klampatsa, A. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.51 · Cited by 8
An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
Snell, D. C., Gunde, T., Warmuth, S., Chatterjee, B., Brock, M., Hess, C., Johansson, M. H., Simonin, A., Spiga, F. M., Weinert, C., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2233401 · Cited by 8
Harmonizing the symphony of chimeric antigen receptor T cell immunotherapy with the elegance of biomaterials
Chen, Z., Hu, Y., & Mei, H. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.07.017 · Cited by 7
Optimising CAR T therapy for the treatment of solid tumors
Mobark, N., Hull, C., & Maher, J. F. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2421194 · Cited by 7
Intratumoral Treatment in Lung Cancer: Is It Time to Move Towards Clinical Practice?
Pagliari, G. G., Colonese, F., Canova, S., Abbate, M. I., Sala, L., Petrella, F., Clementi, T. D., & Cortinovis, D. L. (2024) · Cancers · doi:10.3390/cancers16233892 · Cited by 7
BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer
Zhang, H., Xia, L., Xuzhang, W., Li, Z., Zhang, J., Li, F., Chen, C., Wang, J., Zong, X., Yang, X., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010073 · Cited by 7
Fast tumor-infiltrating lymphocytes (TILs): rapid manufacture of an adoptive cellular therapeutic from pleural infiltrating T cells for intrapleural administration
Donnenberg, V. S., LISTER, J. W., Briedenbaugh, C. L., Wagner, P. L., Bartlett, D. L., & Donnenberg, A. D. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.06.011 · Cited by 7
Genetic Engineering in CAR T Cells for Solid Tumors: Current State, Barriers and Future Developments
Redondo-Frutos, R. A., Justicia-Lirio, P., Barbero-Jiménez, C., Garnica, M., Trudu, L., Rodríguez-Márquez, P., Lasarte, J. J., Prósper, F., & Rodríguez-Madoz, J. R. (2025) · Human Gene Therapy · doi:10.1177/10430342251372041 · Cited by 7
Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies
Sun, Y., Yang, H., Xu, Q., Li, X., Lou, J., Duan, J., Xu, J., Liu, Z., Xia, Y., Lin, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202508754 · Cited by 7
Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations
Silvestri, R., Colucci, E., Piccardi, M., Landi, S., & Gemignani, F. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00379-z · Cited by 7
CAR-T Cell Exhaustion in Cancer over the Past Decade: Mitochondrial Metabolism as a Target for Counteraction
Si, L., Wei, D., Pan, J., Baleeiro, R. B., Chard, L. S., & Wang, Y. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218240 · Cited by 7
PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions
Civelek, A. C. (2026) · Cancers · doi:10.3390/cancers18020234 · Cited by 7
Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers
Barber-Rotenberg, J. S., Haas, A. R., Aggarwal, C., O’Hara, M. H., Hexner, E. O., Pequignot, E. C., Dowd, E., Ndeupen, S., Thai, E., Chen, F., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.021 · Cited by 7
Lung tumouroids as a testing platform for precision CAR T cell therapy
Ehlen, L., Farrera-Sal, M., Szyska, M., Arndt, J., Schallenberg, S., Scholz, C., Yang, M., Vollbrecht, C., Löwa, A., Friedrich, R., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01594-3 · Cited by 7
CAR T-cells in hematologic malignancies: Advances, challenges, and future directions
Hernández-Idarraga, K. J., Arias-Rozo, A. J., Arango-Rodríguez, M. L., Sossa, C., & Becerra‐Bayona, S. M. (2026) · iScience · doi:10.1016/j.isci.2026.115213 · Cited by 7
Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence
Heydari, F., Zendehdel, H., Varkiani, M. M., Fahmi, S., Derakhshani, M., Anvari, S., Farhid, F., Hamblin, M. R., & Naghinezhad, J. (2026) · Biomarker Research · doi:10.1186/s40364-026-00957-5 · Cited by 7
Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1
Quach, H. T., Hou, Z., Bellis, R. Y., Saini, J. K., Amador-Molina, A., Adusumilli, P. S., & Xiong, Y. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2152323 · Cited by 8
Self-citation
Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy
Sah, V. R., Jespersen, H., Karlsson, J. W., Nilsson, L. M., Bergqvist, M., Johansson, I., Carneiro, A., Helgadóttir, H., Levin, M., Ullenhag, G. J., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0490 · Cited by 7
Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents
Sun, Z., Jaswal, A. P., Chu, X., Rajkumar, H., Cortez, A. G., Edinger, R. S., Rose, M., Josefsson, A., Bhise, A., Huang, Z., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c04492 · Cited by 7
CAR-T Cell Therapy for Solid Tumors
Tony, L. T., Stabile, A., Schauer, M. P., Hudecek, M., & Weber, J. (2025) · Transfusion Medicine and Hemotherapy · doi:10.1159/000542438 · Cited by 7
Overcoming biophysical barriers with innovative therapeutic delivery approaches
Pavuluri, S., & Sheth, R. A. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00529-3 · Cited by 7
Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving Combination Strategies
Chen, C., Jung, A., Yang, A.-N., Monroy, I., Zhang, Z.-F., Chaurasiya, S., Deshpande, S., Priceman, S., Fong, Y.-M., Park, A. K., et al. (2023) · Cancers · doi:10.3390/cancers15235661 · Cited by 6
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma
Verma, A., & Rafiq, S. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_5 · Cited by 7
Toward the clinical development of synthetic immunity to cancer
Garcia, J. M., Burnett, C. E., & Roybal, K. T. (2023) · Immunological Reviews · doi:10.1111/imr.13245 · Cited by 9
Current progress in chimeric antigen receptor T‐cell therapy for malignant tumors
Zheng, Y., Huang, J., Xu, Y., & Luo, H. (2024) · MedComm – Future Medicine · doi:10.1002/mef2.79 · Cited by 5
Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future prospects
Liao, Q., Mao, Y., Feng, M., Zheng, N., Ding, X., Zhang, X., Wang, Z., & Xu, J. (2025) · Clinical Cancer Bulletin · doi:10.1007/s44272-025-00050-2 · Cited by 6
Immunocyte reprogramming empowers live-cell drug delivery: Mechanistic insights, delivery strategies, and clinical perspectives
Sun, Z., Ge, J., Fu, H., Chen, Z., Zhao, C., Li, X., Sun, Y., Gao, Z., Li, Y., & Li, Y. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.019 · Cited by 6
Integrating CAR-T therapy with PD-1/PD-L1 blockade: Mechanisms, synergy, and optimized strategies in NSCLC
Li, X., Wang, Z., Mao, S., Zhao, Y., Ye, J., Liang, B., Peng, J., Xie, X., Pan, J., Xiao, C., et al. (2026) · iScience · doi:10.1016/j.isci.2025.114607 · Cited by 6
Adoptive cell therapies in solid tumors: current clinical landscape, challenges, and future directions
Rizkallah, J., Wehbeh, B. E. D., Wassouf, W., Salameh, E., Joumaa, A., Haddad, F. J., Hamade, L., Charbel, N., Bakri, G. M., Awada, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1800292 · Cited by 6
Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice
Zhou, X., Yang, M., Yu, J., Tan, J., Xu, N., Zhou, Y., Zhang, W., Ma, J., Zhang, Z., Friedlaender, A., et al. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-25 · Cited by 6
Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma
Yun, K. M., & Bazhenova, L. A. (2024) · Cancers · doi:10.3390/cancers16071252 · Cited by 6
Pseudoprogression in CAR-T cell therapy for solid tumor: Case report
Zhao, X., Liu, Y., Qin, G., Yan, G., Li, Q., Chen, X., Tian, X., Yu, Y., Ren, J., & Zhang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1504104 · Cited by 6
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells
Ramapriyan, R., Barker, F. G., Richardson, L. G., Sun, J., Vandecandelaere, G., Shim, J. M., Vlaminck, G. D., Gaffey, M., Grewal, E. P., Tazhibi, M., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf155 · Cited by 6
New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma
Aldea, M. D., Benítez, J. C., Chaput, N., & Besse, B. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1046 · Cited by 6
Targeting the interactions between lymphocytes and liver cancer stem cells in combination with immunotherapy is a promising therapeutic strategy
Chen, W., Zhang, X., Yan, Y., Sun, X., & Li, L. (2023) · Hepatoma Research · doi:10.20517/2394-5079.2022.52 · Cited by 6
CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy
Cui, Y., Luo, M., Gu, C., He, Y., Yao, Y., & Li, P. (2023) · Biophysics Reports · doi:10.52601/bpr.2023.230020 · Cited by 6
The application of antibody-based agents in cancer therapy based on their mechanisms of action
Qian, K., Li, G., Zhang, S., Zou, Y., Ai, H., Zheng, X., Fu, W., Lei, C., & Hu, S. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.02.021 · Cited by 6
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
Deiana, C., Fabbri, F., Tavolari, S., Palloni, A., & Brandi, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310415 · Cited by 6
Generating potent and persistent antitumor immunity via affinity-tuned CAR-T cells targeting mesothelin
Yue, Y., Liu, J.-J., Ma, H., Pan, Z., Wang, L., Zhang, J., Wang, S., Xie, Y., Jiang, H., Bian, Y., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01572-0 · Cited by 5
CAR T- cell therapy: A promising novel approach for treatment of cancer
Posa, M. K., Singh, J., Parveen, S., & Panda, S. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101125 · Cited by 5
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Gao, T. A., Shih, R. M., Clubb, J. D., Hung, S.-H., Singh, T., James‐Allan, L. B., DiBernardo, G., Shafer, A. M., Bouren, A., Ceja, M. A., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adw9286 · Cited by 7
Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies
Tsagkaraki, I., Gannon, I., Rampotas, A., Singh, D., Roddy, H., Ottaviani, D., & Roddie, C. (2026) · Cancers · doi:10.3390/cancers18060911 · Cited by 5
Target selection and clinical chimeric antigen receptor T cell activity against solid tumors
Hofe, E. V., Yang, Y., & Jin, M. M. (2023) · iLABMED · doi:10.1002/ila2.8 · Cited by 5
Targeting mesothelin in cancer
Elbi, C. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.100756 · Cited by 5
[Advances in Targeted Therapy for Malignant Pleural Mesothelioma].
Fu, F., Zhang, Y., & Shen, H. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.102.18 · Cited by 5
Strategies for Altering Delivery Technologies to Optimize CAR Therapy
Cao, L., Liu, Y., & Lin, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073206 · Cited by 5
Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma
Sofianidi, A. A., Syrigos, N. K., Blyth, K. G., Charpidou, A. G., & Vathiotis, I. A. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.04.008 · Cited by 5
Hyperthermic Intrathoracic Chemoperfusion and the Role of Adjunct Immunotherapy for the Treatment of Pleural Mesothelioma
Kong, S. L., Feng, Z., Kim, S.-M., Ha, E. K., Kamel, K., Becich, M. J., Luketich, J. D., & Pennathur, A. (2025) · Biomolecules · doi:10.3390/biom15050678 · Cited by 5
Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions
Kouro, T., Sasada, T., & Imai, K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115010 · Cited by 5
Tumor immunotherapy: past, present, and future
Huang, Y., Ge, H., Zhang, Z., Liu, X., Zhong, K., Tong, A., Li, G., & Zhou, L. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002919 · Cited by 6
Tandem Dual CAR-T Cells Targeting HER2 and Mesothelin Enhance anti-Tumor Effects in Pancreatic Cancer
Jiang, F., Zheng, M., Ding, Y., Xiong, F., Liu, X., Zhou, X., Yan, Z., & Luo, J. (2025) · Cancer Investigation · doi:10.1080/07357907.2025.2548603 · Cited by 5
Intrapleural Anticancer Therapy for Malignant Pleural Diseases: Facts or Fiction?
Agrawal, A., Chaddha, U., Shojaee, S., & Maldonado, F. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1769094 · Cited by 5
Targeted Approaches to Treatment of Pleural Mesothelioma: A Review
Dagogo‐Jack, I. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00344 · Cited by 5
Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Hao, Y., Gkasti, A., Managh, A. J., Dagher, J., Sifis, A., Tiron, L., Chriqui, L.-E., Marie, D. N., Silva, O. D. S., Christodoulou, M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0245 · Cited by 5
A Glimpse in the Future of Malignant Mesothelioma Treatment
Pezzicoli, G., Rizzo, M., Perrone, M., Minei, S., Mutti, L., & Porta, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.809337 · Cited by 5
Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe
Castiello, L., Santodonato, L., Napolitano, M., Carlei, D., Montefiore, E., Monque, D. M., D’Agostino, G., & Aricò, E. (2022) · Cancers · doi:10.3390/cancers14215351 · Cited by 5
PD-1 Blocking Strategy for Enhancing the Anti-Tumor Effect of CAR T Cells Targeted CD105
Wang, X., Lai, Z., Pang, Y., Sun, Q., Yang, W., & Wang, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12688 · Cited by 5
Self-citation
Obstacles and improvement strategies for CAR-T cell therapy in solid tumors
Luo, Z., Hu, Q., Ren, M., Wang, L., Zou, Q., Wen, X., Chen, S., Liu, Q., Luo, D., & Guo, Z. (2026) · Discover Oncology · doi:10.1007/s12672-026-04473-8 · Cited by 6
Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies
Khan, A., Mujahid, A., Tareen, A., Amin, A., Khan, S. R., Hadi, D. K., & Raza, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1787086 · Cited by 4
Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic state
Zhang, X., Zhang, C., Lu, S., Dong, J., Tang, N., Wang, Y., Han, W., Pan, X., Zhang, X., Liu, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101869 · Cited by 4
Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin
Smith, K. E. R., Ayers-Ringler, J. R., Orme, J. J., Lucien, F., Kim, Y., Winters, J. L., & Mansfield, A. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-97952-x · Cited by 4
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring
Angelis, B. D., D'Amore, M. L., Lecot, P., Neininger, K., Lorrain, M., Gambotti, L., Dreuillet, C., Courcault, E., Chatterjee, S., Delgado, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1567582 · Cited by 4
Therapeutic T cells with 3-in-1 strategy for the treatment of biliary tract cancer
Wan, X., Zhao, J., Yang, X., Mou, X., Liu, B., Gao, B., Gu, W., & Zhao, H. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102349 · Cited by 4
The Tumor Environment in Peritoneal Carcinomatosis and Malignant Pleural Effusions: Implications for Therapy
Mirsky, P. O., Wagner, P. L., Mandic-Popov, M., Donnenberg, V. S., & Donnenberg, A. D. (2025) · Cancers · doi:10.3390/cancers17193217 · Cited by 4
CAR-T/NK/M-based combination therapies in cancer: A comprehensive review
Vaja, S., Khandelwal, S., Vora, C., Khan, A. A., Wajeed, S., Sk, M. H., & Baig, M. S. (2026) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2026.101269 · Cited by 4
Next generation CAR-T cells to tackle solid tumors
Abreu, T. R., Godinho‐Santos, A., Amaral, A. T., Paiva, A. A., Moreira, J. N., & Gonçalves, J. R. M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114650 · Cited by 5
Cell Therapies and Bispecific Engagers: Redefining Strategies against Checkpoint Resistance
Laubli, H. P., König, D., Donia, M., Binder, M., & Zippelius, A. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3694 · Cited by 5
In vivo CAR-T therapy: from molecular design to precision delivery
Li, H., Wen, W., Zhao, X., & Liang, G. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04232-5 · Cited by 4
CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors
Shen, S., Ruan, Z., Jiang, B., Qiu, W., Zhang, F., & Shu, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1764452 · Cited by 4
Advances in CAR-T cell therapy for malignant solid tumors
Liu, J., Tu, X., Liu, L., & Fang, W. J. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0044 · Cited by 4
CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature
Karam, A., Mjaess, G., Chanzá, N. M., Aoun, F. Y., Kheir, G. B., Younes, H., Kazzi, H., Albisinni, S., & Roumeguère, T. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2125004 · Cited by 4
Image-guided Ablative Procedures
Dai, R., Uppot, R. N., Arellano, R. S., & Kalva, S. P. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.11.037 · Cited by 4
Engineered Cellular Therapies for the Treatment of Thoracic Cancers
Erickson, S. M., Manning, B. M., Kumar, A., & Patel, M. R. (2024) · Cancers · doi:10.3390/cancers17010035 · Cited by 4
Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy
Barjasteh, A. H., Saebi, M., Mahmoudi, M., Kheder, R. K., Hashemy, S. I., Forouzanfar, F., & Esmaeili, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128336391241107112957 · Cited by 4
The road ahead for chimeric antigen receptor T cells
Stewart, C. M., Siegler, E. L., & Kenderian, S. S. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf047 · Cited by 4
Advances in drug treatments for mesothelioma
Zucali, P. A., Vincenzo, F. D., Perrino, M., Digiacomo, N., Cordua, N., D’Antonio, F., Borea, F., Fazio, R., Pirozzi, A., & Santoro, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2072211 · Cited by 4
Accelerating innovations in systemic therapy for pleural mesothelioma
Fennell, D. A., & Bzura, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00419-5 · Cited by 4
What's Current and What's New in Mesothelioma?
Leal, J. L., Hoang, W., Xue, J., Dunne, B., John, T., & Harden, S. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.08.029 · Cited by 4
Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma
Tsuji, S., & Imai, K. (2023) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.99.003 · Cited by 4
New Markers for Management of Mesothelioma
Nash, A., Firth, T., & Creaney, J. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1769097 · Cited by 4
Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement
Assié, J., & Jean, D. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2277224 · Cited by 6

Authors: Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., Pineda, J., Perez-Johnston, R., Tan, K. S., Daly, B., Araujo Filho, J. A., Ngai, D., McGee, E., Vincent, A., Diamonte, C., Sauter, J. L., Modi, S., Sikder, D., Senechal, B., Wang, X., Travis, W. D., Gönen, M., Rudin, C. M., Brentjens, R. J., Jones, D. R., & Sadelain, M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
6Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
5Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Corresponding author: Adusumilli, Prasad S.
ORCID: Adusumilli, Prasad S.
Zauderer, Marjorie G.
Rivière, Isabelle
Solomon, Stephen B.
Rusch, Valerie W.
O'Cearbhaill, Roisin E.
Cheema, Waseem
Chintala, Navin K.
Pineda, John
Perez-Johnston, Rocio
Tan, Kay See
Daly, Bobby
Sauter, Jennifer L.
Modi, Shanu
Wang, Xiuyan
Travis, William D.
Gönen, Mithat
Rudin, Charles M.
Brentjens, Renier J.
Jones, David R.
Sadelain, Michel
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2021-07-15
Volume: 11
Issue: 11
Pages: 2748-2763
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-21-0407
PMC: PMC8563385
OpenAlex: W3179214161
Cited by: 605
References: 37
Citations by year: 2026: 124 · 2025: 119 · 2024: 131 · 2023: 125 · 2022: 90 · 2021: 15
FWCI: 32.88
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: NIH (P30 CA008748, R01 CA236615-01, R01 CA235667)
U.S. Department of Defense (BC132124, LC160212, CA180889)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords: mesothelin, chimeric antigen receptor T cells, CAR T-cell therapy, malignant pleural mesothelioma, malignant pleural effusion, pembrolizumab, anti-PD-1 therapy, intrapleural administration, combination immunotherapy, autologous T cells, safety and tolerability, overall survival
MeSH terms: Mesothelin, Humans, Mesothelioma, Pleural Diseases, Immunotherapy, Adoptive, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks